Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02905331 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis
A Phase 3 study of Psoriasis, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 3
- Development phase
- 78
- Enrollment target
- 14
- Study locations
NCT02905331 is a Phase 3 study of Psoriasis that has completed, run by Janssen Research & Development. The registered enrollment target is 78 participants, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (84% lower). The trial reports 14 study locations across 11 states.
The verdict
NCT02905331, a Phase 3 study of Psoriasis, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 78 participants
- Enrollment target
- 14
- Study locations
Study Summary
The purpose of the study is to evaluate the efficacy, safety, pharmacokinetics, immunogenicity, usability, and acceptability of guselkumab delivered using SelfDose device in participants with moderate to severe plaque-type psoriasis.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Guselkumab
Study Locations (14)
Other
- Niepubliczny Zaklad Opieki Zdrowotnej Osteo-Medic s.c. Artur Racewicz i Jerzy Supronik - Bialystok
- Szpital Uniwersytecki nr 1 im Dr A Jurasza - Bydgoszcz
- Wromedica Irena Bielicka, Janusz Szczepanik S.C. - Wroclaw
Ontario
- Dermatrials Research - Hamilton
- DermEdge Research - Mississauga
Florida
- Renstar Medical Research - Ocala
Illinois
- Arlington Dermatology - Rolling Meadows
Indiana
- Indiana Clinical Trial Center - Plainfield
Kentucky
- Dermatology Specialists - Louisville
Michigan
- Hamzavi Dermatology - Fort Gratiot
Pennsylvania
- University of Pittsburgh Department of Dermatology - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2017-02-28 |
| Est. Completion | 2018-02-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02905331
The ClinicalTrials.gov registry entry for NCT02905331 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (84% lower). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02905331 reports 14 study locations spanning 11 distinct geographic areas - top geographies include Other, Ontario, Florida.
Frequently Asked Questions
What is clinical trial NCT02905331 about?
NCT02905331 is a clinical study titled "Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis". The purpose of the study is to evaluate the efficacy, safety, pharmacokinetics, immunogenicity, usability, and acceptability of guselkumab delivered using SelfDose device in participants with moderate to severe plaque-type psoriasis.
What is the current status of trial NCT02905331?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 78 participants. The study started on 2017-02-28. Estimated completion is 2018-02-06.
What conditions does trial NCT02905331 study?
This clinical trial studies the following conditions: Psoriasis.
What interventions are being tested in trial NCT02905331?
The interventions under investigation include: Placebo (DRUG), Guselkumab (DRUG).
Who is sponsoring clinical trial NCT02905331?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02905331 being conducted?
This trial has 14 study locations across Florida, Illinois, Indiana, Kentucky, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977
ACTIVE NOT RECRUITING · Phase 3
-
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
ACTIVE NOT RECRUITING · Phase 3
-
Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis
ACTIVE NOT RECRUITING · Phase 3
-
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.